Abstract
Purpose To compare the diagnostic performance and to evaluate the interrelationship of electroretinographical and structural and vascular measures in glaucoma.
Methods For 14 eyes of 14 healthy controls and 15 eyes of 12 patients with glaucoma ranging from preperimetric to advanced stages OCT, OCT-A and electrophysiological measures [multifocal photopic negative response ratio (mfPhNR) and steady state pattern electroretinogram (ssPERG)] were applied to assess changes in retinal structure, microvasculature, and function, respectively. The diagnostic performance was assessed via area-under-curve (AUC) measures obtained from ROC analyses. The interrelation of the different measures was assessed with correlation analyses.
Results mfPhNR and ssPERG amplitudes, parafoveal (pfVD) and peripapillary vessel density (pVD), macular ganglion cell inner plexiform layer thickness (mGCIPL) and peripapillary retinal nerve fibre layer thickness (pRNFL) were significantly reduced in glaucoma. The AUC for mfPhNR was highest among diagnostic modalities (AUC: 0.88, 95%-CI: 0.75-1.0, P< 0.001), albeit not statistically different from that for macular (mGCIPL: 0.76, 0.58-0.94, P< 0.05; pfVD: 0.81, .65-.97, P< 0.01) or peripapillary imaging (pRNFL: 0.85, 0.70-1.0, P< 0.01; pVD: 0.82, 0.68-0.97, P < 0.01). Combined functional/vascular measures yielded the highest AUC (mfPhNR-pfVD: 0.94, 0.85-1.0, P<0.001). The functional/structural measure correlation (mfPhNR-mGCIPL correlation coefficient (rs): 0.58, P = 0.001; mfPhNR-pRNFL rs: 0.66, P < 0.0001) was stronger than the functional-vascular correlation (mfPhNR-pfVD rs: 0.29, P = 0.13; mfPhNR-pVD rs: 0.54, P = 0.003).
Conclusions The combination of ERG measures and OCT-A improved diagnostic performance in glaucoma. Combing ERG, structural and OCT-A parameters provides an enhanced understanding of the pathophysiology of glaucoma.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by European Union Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement (No. 675033) and by funding of the German research foundation (DFG; HO2002/20-1) to MBH
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical Committe of Otto von Guericke University
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data available upon reasonable request.
